Status:

TERMINATED

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

Lead Sponsor:

Allergan

Collaborating Sponsors:

TARIS Biomedical, Inc.

Conditions:

Interstitial Cystitis

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

The purposes of the study is to determine if LiRIS®, an investigational drug-delivery system, is safe and tolerable in women with Interstitial Cystitis (IC), and to evaluate any change in IC symptoms ...

Detailed Description

The study is conducted in 2 parts: a randomized, blinded part in which subjects are assigned randomly (by chance) to LiRIS 400 mg or LiRIS placebo; subjects who complete this part and are eligible to ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Blinded study:
  • Women age 18 and over
  • Diagnosed with Interstitial Cystitis as defined by protocol
  • Able to report IC symptoms of bladder pain, voiding habits, as required by protocol, and record in diary
  • Able to comply with visit schedule and diary completion at home
  • Open-label Extension:
  • Must have completed the blinded study prior to screening for the Open-label extension
  • Exclusion Criteria (Blinded and Open-Label Extension):
  • Pregnant or lactating women
  • History or presence of any condition that would make it difficult to accurately evaluate bladder symptoms
  • Bladder or urethral abnormality that would prevent safe insertion of investigational product
  • Requiring medication not allowed per study protocol

Exclusion

    Key Trial Info

    Start Date :

    March 1 2013

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2014

    Estimated Enrollment :

    31 Patients enrolled

    Trial Details

    Trial ID

    NCT01824303

    Start Date

    March 1 2013

    End Date

    December 1 2014

    Last Update

    January 26 2016

    Active Locations (17)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (17 locations)

    1

    Citrus Valley Medical Research , Inc.

    Glendora, California, United States, 91741

    2

    Atlantic Urological Associates

    Daytona Beach, Florida, United States, 32114

    3

    University of Kansas Medical Center

    Kansas City, Kansas, United States, 66160

    4

    The UrogynecologyCenter, LLC

    Overland Park, Kansas, United States, 66209-2002